20/20 Biolabs Inc (AIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Sales | 2,045 | 1,752 |
| Cost of Goods | 1,441 | 1,392 |
| Gross Profit | 605 | 360 |
| Operating Expenses | 4,376 | 6,430 |
| Operating Income | -3,331 | -5,677 |
| Interest Expense | 156 | 13 |
| Other Income | -252 | 138 |
| Pre-tax Income | -3,739 | -5,552 |
| Net Income Continuous | -3,739 | -5,552 |
| Net Income | $-3,739 | $-5,552 |
| EPS Basic Total Ops | -0.76 | -1.16 |
| EPS Basic Continuous Ops | -0.76 | -1.16 |
| EPS Diluted Total Ops | -0.76 | -1.16 |
| EPS Diluted Continuous Ops | -0.76 | -1.16 |
| EBITDA(a) | $-3,138 | $-5,537 |